-transparent.png){kind=logo}
We evaluated the CNS complications in 118 adults with acute leukemia who received IV high-dose Ara-C therapy. Fourteen (12%) had cerebellar signs, encephalopathy, seizures, or leukoencephalopathy. Symptoms usually occurred within 24 hours after the last treatment. Patients receiving a cumulative dose in excess of 24 g/m2 had more severe or irreversible symptoms. After lower cumulative doses, symptoms often resolved even though treatment was continued. The incidence of CNS complications of high-dose Ara-C is acceptable and is potentially reversible if appropriate precautions are taken.
Related Publications
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
June 1985,
Seminars in oncology,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
June 1985,
Seminars in oncology,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
January 1983,
Medical and pediatric oncology,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
December 1981,
Cancer,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
July 1987,
Cancer,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
March 2005,
Annals of oncology : official journal of the European Society for Medical Oncology,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
February 1984,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
December 1990,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
June 1989,
Arthritis and rheumatism,
T L Hwang, and
W K Yung, and
E H Estey, and
W S Fields
June 1987,
Seminars in oncology,
